Azadeh Shahsavar
@azadeh-shahsavar.bsky.social
Structural biologists | Associate professor at the University of Copenhagen | EMBL-Hamburg, DANDRITE AU, and MolBiolAU Alumni.
Thank you, Aritz 🤗
April 26, 2025 at 6:47 AM
Thank you, Aritz 🤗
April 24, 2025 at 8:14 PM
This interdisciplinary research represents nothing less than a tour de force by Ryan P. Cantwell Chater, and a great collaborative effort between the labs of
Robert Vandenberg, Christopher Cioffi, Megan O'mara, Mike Michaelides, Sarasa Mohammadi and myself.
Robert Vandenberg, Christopher Cioffi, Megan O'mara, Mike Michaelides, Sarasa Mohammadi and myself.
April 24, 2025 at 8:14 PM
This interdisciplinary research represents nothing less than a tour de force by Ryan P. Cantwell Chater, and a great collaborative effort between the labs of
Robert Vandenberg, Christopher Cioffi, Megan O'mara, Mike Michaelides, Sarasa Mohammadi and myself.
Robert Vandenberg, Christopher Cioffi, Megan O'mara, Mike Michaelides, Sarasa Mohammadi and myself.
Our findings provide proof-of-concept for the rational design of GlyT2 inhibitors and a clear avenue for novel treatments of chronic neuropathic pain.
April 24, 2025 at 8:14 PM
Our findings provide proof-of-concept for the rational design of GlyT2 inhibitors and a clear avenue for novel treatments of chronic neuropathic pain.
We show that RPI-GLYT2-82 is efficacious at alleviating pain in mouse models of neuropathic pain with no mechanism-based side effects tested at doses up to 5 times the maximal analgesic dose, or addiction liability at up to 3 times the maximal analgesic dose.
April 24, 2025 at 8:14 PM
We show that RPI-GLYT2-82 is efficacious at alleviating pain in mouse models of neuropathic pain with no mechanism-based side effects tested at doses up to 5 times the maximal analgesic dose, or addiction liability at up to 3 times the maximal analgesic dose.
We have determined the first #cryoEM structures of human GlyT2 bound to a potent pseudo-irreversible inhibitor (ORG25543) that failed in pre-clinical studies, a novel and reversible inhibitor (RPI-GLYT2-82), and in the substrate-free state.
April 24, 2025 at 8:14 PM
We have determined the first #cryoEM structures of human GlyT2 bound to a potent pseudo-irreversible inhibitor (ORG25543) that failed in pre-clinical studies, a novel and reversible inhibitor (RPI-GLYT2-82), and in the substrate-free state.
Congratulations!! SLC6 transporters rule!
April 24, 2025 at 7:00 AM
Congratulations!! SLC6 transporters rule!
Thank you, Nadia! ☺️
March 29, 2025 at 9:05 PM
Thank you, Nadia! ☺️
Thanks Stephan!
March 29, 2025 at 2:23 PM
Thanks Stephan!
and the Core Facility for Integrated Microscopy – CFIM – funded by @novo-nordisk.bsky.social where we collected our cryo-EM data on the first batch of newly developed HexAuFoil grids from @quantifoil.bsky.social
March 29, 2025 at 2:12 PM
and the Core Facility for Integrated Microscopy – CFIM – funded by @novo-nordisk.bsky.social where we collected our cryo-EM data on the first batch of newly developed HexAuFoil grids from @quantifoil.bsky.social
Our study will facilitate structure-based design of improved selective inhibitors targeting GAT3 for more efficient treatment of epilepsy and a range of other neurological disorders. We are grateful for the support from
@lundbeckfonden.bsky.social
@novo-nordisk.bsky.social
@DFF_raad
@lundbeckfonden.bsky.social
@novo-nordisk.bsky.social
@DFF_raad
March 29, 2025 at 2:12 PM
Our study will facilitate structure-based design of improved selective inhibitors targeting GAT3 for more efficient treatment of epilepsy and a range of other neurological disorders. We are grateful for the support from
@lundbeckfonden.bsky.social
@novo-nordisk.bsky.social
@DFF_raad
@lundbeckfonden.bsky.social
@novo-nordisk.bsky.social
@DFF_raad
Our inhibitor-bound inward-open GAT3 reveals the binding mode of SR-THAP and the structural determinants of selectivity. Our GABA-bound inward-occluded GAT3 reveals ion coordination and substrate recognition network with exciting distinction to that previously observed for the GAT1 subtype.
March 29, 2025 at 2:12 PM
Our inhibitor-bound inward-open GAT3 reveals the binding mode of SR-THAP and the structural determinants of selectivity. Our GABA-bound inward-occluded GAT3 reveals ion coordination and substrate recognition network with exciting distinction to that previously observed for the GAT1 subtype.
I mean… just saw this:
March 14, 2025 at 7:53 PM
I mean… just saw this:
How is this not illegal?!! 🤯 I can’t understand how/why canceling an ongoing grant is even possible 😮💨
March 11, 2025 at 10:23 PM
How is this not illegal?!! 🤯 I can’t understand how/why canceling an ongoing grant is even possible 😮💨
Hi Erik! Would you add me too? Structural biologist by training, interested in effective targeting of membrane transporters in diseases. ORCID: orcid.org/0000-0001-54...
ORCID
orcid.org
March 9, 2025 at 9:57 AM
Hi Erik! Would you add me too? Structural biologist by training, interested in effective targeting of membrane transporters in diseases. ORCID: orcid.org/0000-0001-54...
Oh, wow, completely had forgotten about these safety tests. I’ll get to do it soon hopefully at Petra III - starting a SSX project 🥲
March 4, 2025 at 5:17 PM
Oh, wow, completely had forgotten about these safety tests. I’ll get to do it soon hopefully at Petra III - starting a SSX project 🥲
This looks so much better (safer) than what we use..
March 3, 2025 at 7:49 PM
This looks so much better (safer) than what we use..
I had such an amazing day, Nadia! Thanks for having me 🤗
February 11, 2025 at 6:29 PM
I had such an amazing day, Nadia! Thanks for having me 🤗